News

The FDA has approved Dsuvia (sufentanil) sublingual tablets for use in medically supervised healthcare settings such as hospitals, surgical centers, and emergency departments for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Endo Pharmaceuticals is voluntarily recalling two lots of Robaxin (methocarbamol tablets) due to incorrect daily dosing information on the label, which misstates the daily dose as “two to four tablets four times a day,” which could result in 16 tablets, rather than the correct dosage of “two tablets three times daily,” which results in 6 tablets.

The Drug Enforcement Agency (DEA) announced that Epidiolex (cannabidiol) oral solution, a drug derived from marijuana, will be rescheduled from a schedule I drug to a schedule V drug.

The FDA has approved Ajovy (fremanezumab-vfrm) injections for the preventive treatment of migraines. Ajovy will be available in 225 mg monthly doses, or 675 mg quarterly doses.